Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company’s glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer’s disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
Market Cap:300M; Shares Outstanding:52.2M; Short Interest: 15.11%; Q3 2019(9/30/19): Cash 417M. Loss 107M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 230，no change
Shares hold: 5099.41k shares. no change
shares% hold: 97.61%，no change